Study study type PathologyT1T0Patientssample sizesROB Results

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus placebo plus SoC
pembrolizumab plus SoC
KEYNOTE-189, 2018
  NCT02578680
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)pembrolizumab plus pemetrexed plus platineplacebo plus pemetrexed plus platineparticipants with advanced or metastatic nonsquamous non-small cell lung cancer who have not previously received systemic therapy for advanced disease410 / 206low
conclusif
  • demonstrated 51 % decrease in deaths (OS) (PE)
  • demonstrated 48 % decrease in progression or deaths (PFS) (PE)
  • suggested 44 % decrease in deaths (OS) (extension)
  • suggested 52 % decrease in PFS (extension)
  • more...

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus placebo plus SoC
pembrolizumab plus SoC
KEYNOTE-407, 2018
  NCT02775435
RCTsquamous - mNSCLC - L1 - all populationpembrolizumab plus platine and (nab)paclitaxelplacebo plus platine and (nab)paclitaxelpatients with confirmed stage IV squamous NSCLC who had received no previous systemic therapy for metastatic disease278 / 281low
conclusif
  • demonstrated 36 % decrease in deaths (OS) (PE)
  • demonstrated 44 % decrease in progression or deaths (PFS) (PE)